HUTCHMED (China) Limited Sponsored ADR (HCM)
(Delayed Data from NSDQ)
$21.78 USD
+0.03 (0.14%)
Updated May 13, 2024 04:00 PM ET
After-Market: $21.76 -0.02 (-0.09%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
HCM 21.78 +0.03(0.14%)
Will HCM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for HCM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HCM
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
HCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
Other News for HCM
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
Hutchmed initiates Phase 2/3 trial of Surufatinib and Camrelizumab combination
Hutchmed Shareholders Approve All AGM Resolutions
HUTCHMED AGM Concludes with Solid Shareholder Approval